Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma

The phase III MMY-3021 study compared safety and efficacy of subcutaneous versus intravenous administration of the proteasome inhibitor bortezomib in patients with relapsed myeloma. The initial report demonstrated non-inferior efficacy with subcutaneous versus intravenous bortezomib for the primary...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Arnulf, Bertrand, Pylypenko, Halyna, Grosicki, Sebastian, Karamanesht, Ievgenii, Leleu, Xavier, van de Velde, Helgi, Feng, Huaibao, Cakana, Andrew, Deraedt, William, Moreau, Philippe
Formato: Artigo
Idioma:Inglês
Publicado em: Ferrata Storti Foundation 2012
Assuntos:
Original Articles and Brief Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3685287/
https://ncbi.nlm.nih.gov/pubmed/22689676
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2012.067793
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados